U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07189377) titled 'Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors' on Sept. 09.
Brief Summary: The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Hepatitis B Virus (HBV)
Lung Transplant Recipient
Intervention:
DRUG: Entecavir
Recipients will receive 1mg administered orally, beginning pre-transplant as soon as the patient arrives to the hospital for surgery, and then 1mg post-operatively administered orally or via nasogastric tube once d...